Nintedanib in chronic fibrosing interstitial lung diseases. A case series

Abstract

Progressive pulmonary fibrosis (PPF) can be fatal in non-idiopathic interstitial lung diseases. We report a descriptive series of 13 patients with PPF who received treatment with nintedanib, a multitargeted tyrosine kinase inhibitor with antifibrotic effect. Although the reduced number of patients and the observational nature of a case series prevent us from providing strong evidence, our results suggest that nintedanib could be effective in PPF of various etiologies. Nintedanib could also be useful in specific populations such as patients awaiting lung transplant and elderly patients.

Keywords

• Non-idiopathic interstitial lung diseases
• Progressive pulmonary fibrosis
• Antifibrotic therapy
• Nintedanib